Cyclerion Therapeutics, Inc. (CYCN) Stock Profile — Insider Trades & Financials

Revenue$1.0M

Net Income-$799.0K

EPS$-0.92

Market Cap$12.5M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Regina Graul

CEO & Executive Director

Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Founded: 2018
Employees: 1
Headquarters: Cambridge, Massachusetts, United States

⚡

Core Efficiency

ROE?

-8.79%

ROA?

-8.00%

Op. Margin?

-81.76%

📊

Profitability Ratios

Net Margin?

-77.95%

Current Ratio?

5.15

Loading company sections...

Cyclerion Therapeutics, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness